Multiomics medicine in oncology: assessing effectiveness, cost–effectiveness and future research priorities for the molecularly unique individual

Author： Doble Brett   Harris Anthony   Thomas David M   Fox Stephen   Lorgelly Paula  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.12, 2013-09, pp. : 1405-1417

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

On Pharmacogenomics and Cost-Effectiveness Analysis at the Individual Level

By Adis International Limited  

PharmacoEconomics, Vol. 23, Iss. 5, 2005-01 ,pp. : 527-527

Adis International

Access to resources Recommend Favorite

Future Drug Prices and Cost-Effectiveness Analyses

By Hoyle Martin  

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 589-602

Adis International

Access to resources Recommend Favorite

Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. : 284-296

Bentham Science Publishers

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine   Shabaruddin Fatiha H  

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

The future of comparative effectiveness research

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 613, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite